08:23 AM EDT, 09/10/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said it has received "positive feedback" from its pre-Investigational New Drug meeting with the US Food and Drug Administration for its Bria-PROS+ as a potential treatment of advanced prostate cancer.

The meeting was a step toward conducting a phase 1/2 study of the treatment.

As a result of the meeting, the company said the FDA waived the animal toxicology and animal pharmacokinetic studies requirements, simplifying the pathway for Bria-PROS+.

Price: 0.6411, Change: -0.01, Percent Change: -1.40